-+ 0.00%
-+ 0.00%
-+ 0.00%

Lexeo says LX2006 Phase I/II Friedreich ataxia data show early efficacy in JAMA Cardiology publication

PUBT·06/17/2026 20:01:16
Listen to the news
Lexeo says LX2006 Phase I/II Friedreich ataxia data show early efficacy in JAMA Cardiology publication
  • Lexeo Therapeutics reported Phase I/II LX2006 gene-therapy results in Friedreich ataxia, published in JAMA Cardiology.
  • Findings showed the treatment was generally well tolerated, with early signs of benefit across cardiac and neurologic outcomes.
  • SUNRISE-FA 2 pivotal study remains on track to start in Q2 2026, with topline data expected in 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606171601PRIMZONEFULLFEED9748704) on June 17, 2026, and is solely responsible for the information contained therein.